Analysts Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) PT at $29.50

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have been assigned a consensus rating of “Moderate Buy” from the thirteen research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $29.50.

Several brokerages recently issued reports on ARCT. Roth Mkm began coverage on shares of Arcturus Therapeutics in a research report on Thursday, January 22nd. They issued a “buy” rating and a $20.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research report on Wednesday, January 21st. B. Riley Financial began coverage on shares of Arcturus Therapeutics in a research report on Wednesday, March 18th. They issued a “buy” rating and a $22.00 target price for the company. Citigroup cut their target price on shares of Arcturus Therapeutics from $66.00 to $21.00 and set a “buy” rating for the company in a research report on Thursday, March 5th. Finally, Piper Sandler cut their target price on shares of Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating for the company in a research report on Wednesday, March 4th.

Institutional Trading of Arcturus Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. boosted its position in Arcturus Therapeutics by 51.8% during the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 738 shares during the period. BNP Paribas Financial Markets boosted its position in Arcturus Therapeutics by 163.4% during the second quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 2,586 shares during the period. Compagnie Lombard Odier SCmA purchased a new stake in Arcturus Therapeutics during the third quarter valued at about $111,000. CANADA LIFE ASSURANCE Co boosted its position in Arcturus Therapeutics by 27.5% during the third quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 1,567 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in Arcturus Therapeutics by 42.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,760 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 2,313 shares during the period. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

Arcturus Therapeutics Stock Up 2.6%

Arcturus Therapeutics stock opened at $8.84 on Tuesday. Arcturus Therapeutics has a 52 week low of $5.85 and a 52 week high of $24.17. The business has a 50-day simple moving average of $7.59 and a 200 day simple moving average of $9.08. The stock has a market cap of $251.23 million, a price-to-earnings ratio of -3.71 and a beta of 2.44.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its earnings results on Tuesday, March 3rd. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.11). Arcturus Therapeutics had a negative return on equity of 29.13% and a negative net margin of 80.19%.The company had revenue of $7.20 million during the quarter, compared to analysts’ expectations of $14.32 million. On average, research analysts anticipate that Arcturus Therapeutics will post -2.22 earnings per share for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.